Equities

MediciNova Inc

MediciNova Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.39
  • Today's Change0.004 / 0.32%
  • Shares traded2.86k
  • 1 Year change-36.04%
  • Beta0.7058
Data delayed at least 15 minutes, as of May 22 2024 20:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

  • Revenue in USD (TTM)1.00m
  • Net income in USD-8.41m
  • Incorporated2000
  • Employees13.00
  • Location
    MediciNova IncSUITE 650, 4275 EXECUTIVE SQUARELA JOLLA 92037United StatesUSA
  • Phone+1 (858) 373-1500
  • Fax+1 (858) 404-0048
  • Websitehttps://medicinova.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bioqual Inc62.86m957.02k64.85m108.0067.761.6718.491.031.071.0770.2843.411.04--2.99--1.598.141.809.5214.1319.361.527.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
Turnstone Biologics Corp0.00-74.92m64.99m82.00--0.8123-----3.53-3.530.003.460.00----0.00-80.25---94.45--------------0.00---73.66---78.05------
enVVeno Medical Corp0.00-22.12m65.45m31.00--1.54-----1.70-1.700.003.180.00----0.00-54.31-58.43-56.14-62.76-------260,799.30----0.00------4.67--21.58--
Celularity Inc14.79m-181.41m65.78m225.00--1.93--4.45-10.51-10.510.83761.560.04982.292.0365,724.45-61.05---82.37--21.19---1,226.72--0.136618.400.5365---15.75--114.18------
Intensity Therapeutics Inc0.00-15.13m66.37m5.00--6.83-----1.10-1.100.000.7090.00----0.00-206.66---696.72--------------0.00-------56.45------
Ikena Oncology Inc3.85m-70.09m66.60m34.00--0.4287--17.31-1.58-1.580.08613.220.0237----89,488.38-43.11-29.72-46.56-34.62-----1,821.54-294.90----0.00---41.3556.050.8711--6.30--
Rallybio Corp0.00-76.28m66.73m43.00--0.6828-----1.88-1.880.002.360.00----0.00-58.30---62.32--------------0.00-------11.87------
Lantern Pharma Inc0.00-17.53m67.57m21.00--1.89-----1.62-1.620.003.320.00----0.00-36.82-28.83-39.63-30.17------------0.00-------11.93------
Medicinova Inc1.00m-8.41m68.17m13.00--1.14--68.17-0.1714-0.17140.02041.220.0149----76,923.08-12.55-15.36-13.06-15.90-----840.85-1,182.54----0.00------39.08--15.87--
LAVA Therapeutics NV12.54m-28.59m69.67m37.00--1.38--5.56-1.07-1.070.46681.930.107--9.09338,837.80-24.40---28.91--79.64---228.02------0.108---65.09---31.55------
Landos Biopharma Inc0.00-24.80m69.71m19.00--3.00-----3.99-3.990.007.430.00----0.00-61.17-59.84-70.67-72.15-------795.80---594.020.00------44.15------
Earth Science Tech Inc5.98m330.94k70.84m8.00234.3832.82133.8511.840.0010.0010.01950.00693.1611.41106.07747,970.0017.50-224.8442.70--62.2937.795.53-333.580.386-0.38990.1023--243.77-36.31-111.95------
CEL-SCI Corp0.00-29.95m70.95m43.00--4.95-----0.6304-0.63040.000.26450.00-------87.78-70.19-103.56-78.31-------15,434.151.18-39.260.4319------13.99--223.59--
Regencell Bioscience Holdings Ltd0.00-7.45m71.18m12.00--4.17-----0.5863-0.58630.001.310.00----0.00-82.73---113.11--------------0.00------21.15------
Data as of May 22 2024. Currency figures normalised to MediciNova Inc's reporting currency: US Dollar USD

Institutional shareholders

17.37%Per cent of shares held by top holders
HolderShares% Held
3D Investment Partners Pte Ltd.as of 17 Apr 20245.50m11.22%
BlackRock Fund Advisorsas of 31 Mar 2024688.08k1.40%
The Vanguard Group, Inc.as of 31 Mar 2024607.73k1.24%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024447.96k0.91%
Geode Capital Management LLCas of 31 Mar 2024437.86k0.89%
Renaissance Technologies LLCas of 31 Mar 2024230.40k0.47%
SSgA Funds Management, Inc.as of 31 Mar 2024157.20k0.32%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024153.47k0.31%
Merrill Lynch International (Investment Management)as of 31 Mar 2024148.46k0.30%
Bridgeway Capital Management LLCas of 31 Mar 2024145.15k0.30%
More ▼
Data from 31 Mar 2024 - 07 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.